

**Regd. Office :**

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 8337

October 31, 2013

Bombay stock Exchange Limited
1st Floor, P.J. Towers
Dalai Street
MUMBAI – 400 001

Kind Attn.: Mr. Kapoor
Mr. Goopaikrishnan

✓
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra – (East)
Mumbai – 400 051

Kind Attn.: Famroze Pochara
Asst. Vice President

Ahmedabad Stock Exchange Limited
Kamdhenu Complex
Opp. Sahajanand College
Panjara Pole,
Ahmedabad – 380 015

Kind Attn.: Mr. K. K. Mishra

Dear Sirs

Re.: Unaudited financial results for the quarter/half-year ended on September 30, 2013.

We are forwarding herewith **unaudited financial results** for the quarter/half-year ended on September 30, 2013 reviewed by **Audit Committee** and taken on record by the Board of Directors on October 31, 2013 pursuant to **Clause 41** of the Listing Agreement; the same may please receive in order

Thanking you

Yours faithfully
For CADILA HEALTHCARE LIMITED

UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above



Cadila Healthcare Limited

Registered Office: Zydus Tower, Satalra Cross Road, Ahmedabad - 380015.

Tel. No.: (+91-79) 2686-8100 Fax No.: (+91-79) 2656-2365/56 Web Site: www.zydus.com

PART I

Statement of Results for the Quarter and Six Months Ended 30/09/2013

RUPES IN LACS				RUPES IN LACS			
CONSOLIDATED				COMPANY			
3 Months ended 30/09/2013 (Unaudited)	Corresponding 3 months ended 30/09/2012 (Unaudited)	Year to date figures for the current period ended 30/09/2013 (Unaudited)	Sr. No.	Particulars	Corresponding 3 months ended 30/09/2012 (Unaudited)	Year to date figures for the current period ended 30/09/2013 (Unaudited)	Previous year ended 30/09/2012 (Audited)
173,750	164,533	338,383	1	Income from operations	166,886	322,945	297,810
3,925	3,888	7,813	2	a. Net sales	3,188	6,157	8,157
169,825	160,645	330,570	3	b. Other income	163,698	316,788	289,653
4,854	2,560	7,414	4	c. Total income from operations (net)	166,886	322,945	305,963
174,679	163,105	338,384	5	Expenses	191,309	371,679	341,507
41,255	38,511	79,766	6	a. Cost of materials consumed	51,741	94,141	94,141
29,612	21,740	51,352	7	b. Inclusion of stock in trade	17,833	13,407	13,407
(3,243)	(5,786)	(8,979)	8	c. Changes in inventories of finished goods, work in progress and stock on hand	(2,780)	1,574	1,574
27,297	26,100	53,607	9	d. Employee benefits expense	26,494	27,295	27,295
5,176	4,712	9,888	10	e. Depreciation and amortisation expense	6,286	5,574	5,574
53,704	54,937	108,641	11	f. Other expenses	55,501	117,343	117,343
153,801	139,348	293,639	12	g. Total expenses	168,023	348,377	308,023
20,878	23,867	44,745	13	Profit/(Loss) from Operations before other income, finance costs and exceptional items (1-2)	28,863	74,266	36,940
1,229	1,253	2,476	14	h. Other income	2,521	2,915	2,915
22,401	25,120	47,221	15	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	31,384	77,181	39,855
1,938	2,384	4,317	16	i. Finance costs	2,470	6,862	11,102
20,468	22,736	42,904	17	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	28,914	70,319	28,743
0	0	0	18	j. Exceptional items	0	0	0
20,468	22,736	42,904	19	Profit/(Loss) from ordinary activities before tax (7+8)	28,914	70,319	28,743
1,011	2,031	3,042	20	k. Tax expense	3,175	3,108	3,108
19,457	20,705	39,862	21	Net Profit/(Loss) from ordinary activities after tax (9-10)	25,739	67,211	25,635
0	0	0	22	l. Share of profit/(Loss) of associates	0	0	0
19,457	20,705	39,862	23	Net Profit/(Loss) for the period (11-12)	25,739	67,211	25,635
0	0	0	24	m. Share of profit/(Loss) of associates	0	0	0
(8,201)	(7,591)	(15,792)	25	n. Minority interest	0	0	0
11,256	18,296	34,054	26	Net Profit/(Loss) after taxes, minority interest and share of profit/(Loss) of associates (13+14+15)	25,739	67,211	25,635
10,237	10,237	20,468	27	o. Add up equity share capital (Face Value Rs. 5/-)	10,237	20,468	20,468
0	0	0	28	p. Reserves including Reserve for Retention of previous year	0	0	0
0	0	0	29	q. Earnings per share (before extraordinary items)	0	0	0
8.96	9.53	18.48	30	r. Earnings per share (after extraordinary items)	8.96	18.48	18.48
8.96	9.53	18.48	31	s. Earnings per share (after extraordinary items)	8.96	18.48	18.48
8.96	9.53	18.48	32	t. Earnings per share (after extraordinary items)	8.96	18.48	18.48
8.96	9.53	18.48	33	u. Earnings per share (after extraordinary items)	8.96	18.48	18.48

Notes :

- The above results for the quarter ending 30/09/2013 were reviewed by the Audit Committee on October 10, 2013 and then approved by the Board of Directors at their meeting held on October 30, 2013.
- The Statutory Auditors of the company have certified that the results as per Clause 41 of the Listing Agreement.
- The Scheme of Amalgamation of Zydus Healthcare Limited, Zydus Atrial Health Limited and Zydus Pharmaceuticals Limited with the Company from the approved date of April 1, 2012, has been sanctioned by the Hon'ble High Court of India. Pursuant to the Scheme becoming effective on August 16, 2013, the figures for the previous quarter/ six months have been stated for the purpose of meaningful comparison with the figures of current quarter/ six months.
- The Company has incorporated Zydus Pharmaceuticals Limited as a wholly owned subsidiary company, in the state of Gujarat on October 4, 2013.
- The changes in investments during the quarter are as under:
Zydus Pharmaceutical Private Limited (Additional Investments) - Rs. 5,278 Lacs
Zydus BSA Pharma Private Limited (Additional Investments) - Rs. 150 Lacs
Consolidated tax expense is not at the rate of 10% Minimum Tax (MAT) Credit amounting to Rs. 21.20 lacs for the quarter and Rs. 4,468 lacs for the six months ended on September 30, 2013 which is recognized as an asset in accordance with guidance note issued by the Institute of Chartered Accountants of India.
- Figures of previous reporting period have been retrospectively restated wherever necessary to correspond with the figures of the current reporting period.
- The Company has one segment activity viz., "Pharmaceuticals".

By Order of the Board:
For Celia Healthcare Limited:

Director & Managing Director